Loading organizations...
§ Private Profile · Boulder, CO, USA
Biopharmaceutical company developing orally available small molecule therapies for obesity and metabolic disorders.
Ambrosia Biosciences is a Boulder, Colorado-based drug discovery company developing orally delivered, small-molecule therapies for obesity and other metabolic disorders. The biotechnology firm operates fully integrated biology and chemistry laboratories to advance programs targeting incretins and class B G protein-coupled receptors from hit identification to investigational new drug filings. Operating with a dedicated scientific staff of approximately fifteen employees, the enterprise has raised $25 million in total capital to date. This financing includes a $16 million Series A venture round led by institutional investors BVF Partners and Boulder Ventures to support preclinical research and scale laboratory operations. The organization utilizes a research team largely composed of former Array BioPharma scientists and recently appointed industry veteran Jason Haddock to its board of directors. Ambrosia Biosciences was established in 2024 by founder and chief executive officer Nick Traggis.
Ambrosia Biosciences has raised $41.0M across 2 funding rounds.
Ambrosia Biosciences has raised $41.0M in total across 2 funding rounds.
Ambrosia Biosciences has raised $41.0M in total across 2 funding rounds.
Ambrosia Biosciences's investors include Kyle Lefkoff, Merck, Boulder Ventures.
Ambrosia Biosciences has raised $41.0M across 2 funding rounds. Most recently, it raised $25.0M Series A in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 11, 2024 | $25M Series A | Kyle Lefkoff, Merck | — | Announced |
| Aug 21, 2024 | $16M Series A | Boulder Ventures | — | Announced |